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People suffering from neurogenic bowel dysfunction (NBD) and an ineffective bowel regi-
men often suffer from fecal incontinence (FI) and related symptoms, which have a huge
impact on their quality of life. In these situations, transanal irrigation (TAI) has been shown
to reduce these symptoms and improve quality of life.
Aim
To investigate the long-term cost-effectiveness of initiating TAI in patients with NBD who
have failed standard bowel care (SBC).
Methods
A deterministic Markov decision model was developed to project the lifetime health eco-
nomic outcomes, including quality-adjusted life years (QALYs), episodes of FI, urinary tract
infections (UTIs), and stoma surgery when initiating TAI relative to continuing SBC. A data
set consisting of 227 patients with NBD due to spinal cord injury (SCI), multiple sclerosis,
spina bifida and cauda equina syndrome was used in the analysis. In the model a 30-year
old individual with SCI was used as a base-case. A probabilistic sensitivity analysis was
applied to evaluate the robustness of the model.
Results
The model predicts that a 30-year old SCI patient with a life expectancy of 37 years initiating
TAI will experience a 36% reduction in FI episodes, a 29% reduction in UTIs, a 35% reduc-
tion in likelihood of stoma surgery and a 0.4 improvement in QALYs, compared with patients
continuing SBC. A lifetime cost-saving of £21,768 per patient was estimated for TAI versus
continuing SBC alone.
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Conclusion
TAI is a cost-saving treatment strategy reducing risk of stoma surgery, UTIs, episodes of FI
and improving QALYs for NBD patients who have failed SBC.
Introduction
Damage to the central nervous system has a profound impact on the function of the large bowel
and anorectum. Spinal cord injury (SCI), multiple sclerosis (MS), spina bifida (SB), and cauda
equina syndrome (CE) are the most common cause of neurogenic bowel dysfunction (NBD), of
which constipation and fecal incontinence (FI) are the most frequently reported consequences.
NBD affects around 80% of SCI patients [1], and 34% of SB patients [2]. Furthermore, 68% of a
MS population has been shown to suffer from constipation and/or FI [3]. Appropriate pharma-
cological management of bowel dysfunction can be challenging in that laxatives used to treat con-
stipation or antidiarrheal drugs to treat FI carry the risk of incontinence due to loose stool or
constipation, respectively. Nevertheless, without intervention, people with NBD suffer from
reduced quality of life including loss of independence and control, feelings of embarrassment,
anxiety and depression as well as social isolation and loss of sexual relationships [4,5].
Neurogenic bowel is also the source of considerable morbidity including urinary tract infec-
tions (UTIs), hemorrhoids, abdominal pain, rectal bleeding and prolapse, anal fissure, and auto-
nomic dysreflexia [6–8]. These may result in additional hospital admissions. In order to regain
control and optimize comfort, safety and privacy, it is critical to establish a bowel management
program that is effective, timely, and sustainable with minimum physical and pharmacological
interventions used [9]. A stepped pyramidal approach to treatment of bowel dysfunction has
been proposed [10]. Conservative treatment options such as adjustment of diet/fluid intake, gen-
eral lifestyle alteration, oral medications including stool softeners and laxatives, digital stimula-
tion, suppositories and biofeedback constitute the base layer of the pyramid and are referred to as
standard bowel care (SBC). If this is unsuccessful, the next step is to consider a minimally inva-
sive treatment option, transanal irrigation (TAI). The upper layers of the pyramid comprise the
more invasive treatment options such as nerve stimulation implants and surgical colonic irriga-
tion. For patients refractory to these treatments, creation of a stoma may be needed [10].
TAI of the rectum and colon is intended to assist the evacuation of feces from the bowel by
introducing water via the anus, and the method has been demonstrated superior to SBC [11].
Use of TAI reduces episodes of FI [12], improves quality of life [13], reduces time spent on
bowel management compared with previous methods [12,13] and is well tolerated by patients
[14,15]. Furthermore, TAI has been shown to result in a lower total cost to society than stan-
dard bowel management, based on efficacy outcomes from a randomized controlled trial in an
SCI population [12]. However, to date no studies have considered the cost-effectiveness,
including prospectively collected health-related quality of life (HRQoL) data, for long-term use
of TAI in the NBD population. Hence, the aim of the current study was to investigate the long-
term cost-effectiveness of the Peristeen TAI system (Coloplast A/S, Humlebaek, Denmark) in
patients with NBD and an ineffective SBC regimen.
Materials and Methods
Ethic statement
Data used in this study was collected as approved by The National Hospital for Neurology and
Neurosurgery & Institute of Neurology Joint Research Ethics Committee, reference number
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Design of decision model
Markov models are valuable when modelling disease progression over time and therefore com-
monly applied for economic evaluation of healthcare interventions within the chronic or long-
term disease area. A Markov model assumes a finite number of health states where the patient
can transition between and where the cycle length is determined by e.g. treatment failure and
subsequent optimization. In the present study, a deterministic Markov model was developed in
Microsoft Excel1 (Microsoft Corporation, Redmond, WA) to evaluate the cost-effectiveness of
initiating Peristeen TAI in combination with SBC in patients who had failed SBC versus con-
tinuation of SBC alone. An overview of the Markov model is presented in Fig 1 (representing
each of the two treatment options under assessment). The model structure is based on the
stepped pyramidal approach for treatment of NBD and illustrates the stepwise treatment
modalities the patients may receive over their life expectancy. After each cycle, patients can
either a) continue on TAI, b) transition to resume SBC (TAI patients only), c) transition to sur-
gical interventions or d) transition to stoma surgery. Surgical interventions cover sacral nerve
stimulation (SNS), sacral anterior root stimulation (SARS) and antegrade continence enema
(ACE). Stoma surgery was defined as the absorbing state; once entered, it was not possible to
transit to any other treatment states. Death was possible from all health states. A cycle length of
six months was applied to the model throughout a lifetime time horizon, corresponding to the
length of time a patient had to spend on failing SBC to be assessed as eligible for TAI. The time
horizon corresponded to the gender-weighted life expectancy of an SCI patient diagnosed at
age 30 with paraplegia A, B or C/SCI/ D [16] and was used as a base case. The model applied a
United Kingdom (UK) National Healthcare Service (NHS) perspective and discount rates for
costs and benefits of 3.5% p.a. Table 1 provides an overview of the transition probabilities
applied in the Markov model.
Fig 1. Data and Markovmodel overview. The boxes represent the health states that a neurogenic patient can transition between after having failed
standard bowel care (SBC) before and after 2007. SBC alone. After having failed SBC >6 months, a patient can either a) Resume SBC, b) Progress to
SNS/SARS/ACE or d) Progress to stoma (absorbing state). TAI in combination with SBC. After having failed SBC >6 months, a patient can either a)
Initiate Peristeen TAI, b) Resume SBC, c) Progress to SNS/SARS/ACE or d) Progress to stoma. The model assumes that patients do not transition
directly from SBC/TAI to stoma. Transition probabilities have been obtained for each 6-month model cycle using GoalSeek in Excel.
doi:10.1371/journal.pone.0159394.g001
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Data sources
Data was collected at three clinics in the UK: University College Hospital London, Queen
Square and Royal National Orthopaedic Hospital Stanmore. Since 2006, patients with bowel
dysfunction, due to a neurological disorder, and referred to one of the three clinics, were added
to the database. The database comprises demographic and neurological disease details as well
as bowel diary data and questionnaires. Assessment is made at first visit (baseline) at the clinic
and then annually thereafter in terms of the bowel parameters. The annual assessments are
made at a routine clinical face-to-face visit, supported by email reminders sent a month before.
The clinician or nurse specialists may if needed follow-up by phone for any missing data.
Between 350 and 390 new referral are seen per year; compliance with annual follow-up is
between 89 and 93% of available (namely those alive and able to communicate) patients. TAI
was introduced as a treatment option in 2007. TAI was deemed suitable for patients, who had
failed SBC according to the ‘best practice’ criteria’s [10], defined as those who, after at least 6
months use of two classes of laxatives, still experienced: recurrent fecal impaction, fecal urgency
or incontinence, dissatisfaction with time spent toileting, dependence on cares, significant
complications of constipation (abdominal pain, bloating), or negative impact on quality of life
due to bowel symptoms. The prospective real-life data set used in this analysis consisted of 227
patients with NBD and a diagnosis of SCI (n = 116), MS (n = 62), CE (n = 27), SB (n = 15) or
another neurological diagnosis (See Table 2 for baseline demographics). Retrospective data
from 371 NBD patients pre-TAI introduction in 2007 was used to identify the proportion of
patients progressing to stoma, when not having TAI as an option in the treatment pyramid.
The protocols used for NBD management followed the available standards [9,10].
Aggregate data was collected on healthcare resource utilization and the number of patients
on subsequent treatment interventions at the end of follow-up. The data set contained infor-
mation on frequency of FI as well as resource utilization, including number of treated urinary
tract infections (UTIs), hospital admissions, and visits to general practitioner (GP), medical
specialists and dieticians. The data set, including healthcare resource utilization data, was
based on self-reported recall and validated in the corresponding electronic patient journals.
The proportions of patients who had transitioned from TAI to another treatment state by
the end of the follow-up period were converted to six-monthly transition probabilities [17].
Table 1. Overview of transition probabilities applied in the model.
Transition to/from:
Peristeen TAI + SBC
Peristeen TAI Resume SBC SNS/SARS/ACE Stoma
Peristeen TAI 0.9810 0.0069 0.0065 0.0057
Resume SBC 0.0000 0.9692 0.0113 0.0195
SNS/SARS/ACE 0.0000 0.0000 0.9891* 0.0109*
Stoma 0.0000 0.0000 0.0000 1.0000
SBC alone
Peristeen TAI Resume SBC SNS/SARS/ACE Stoma
Peristeen TAI N/A N/A N/A N/A
Resume SBC N/A 0.9736 0.0097 0.0167
SNS/SARS/ACE N/A 0.0000 0.9831* 0.0116*
Stoma N/A 0.0000 0.0000 1.0000
*Transition probabilities have been obtained for each 6-month model cycle using GoalSeek in Excel. SNS: Sacral Nerve Stimulation. SARS: Sacral Anterior
Root Stimulation. ACE: Antegrade Continence Enema.
doi:10.1371/journal.pone.0159394.t001
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The estimated transition probabilities are presented in Table 2. The ‘goal seeking’ functionality
in Excel was used to estimate transition probabilities from surgical interventions (SNS/SARS/
ACE) to stoma by aligning the predicted proportions of patients receiving stoma at six and
seven years in the model with the observed data. No long-term studies have been undertaken
that are powered to detect mortality differences. It was therefore assumed that survival did not
differ between the treatment options, hence the average life expectancy of an SCI patient was
applied to both treatments.
Health related quality of life data was collected at baseline and at each annual follow-up visit
using the EuroQoL-5D (EQ-5D) instrument, and subsequently mapped to generate single
health state utility values (HSUV) on a scale from 0 (death) to 1 (perfect health) based on the
UK value set [18]. Linear regression models were used to estimate disutility for patients over
time. The variables for time and treatment were not significant; therefore point estimates of
HSUVs at 12 months for TAI and SBC were entered into the model. Other HSUVs and decre-
ments for UTI and hospitalization were obtained from the literature (Table 3).
Table 2. Baseline demographics of real-life data from 227 patients.
All SCI CE MS SB Other
Number of participants (n = 227) (n = 116) (n = 27) (n = 62) (n = 15) (n = 7)
Male:Female 119:108 67:49 17:10 25:37 6:9 4:3
% (52:48) (58:42) (63:37) (40:60) (40:60) (57:43)
Mean age (years) 44 43 50 48 24 51
(range) (17–76) (22–71) (20–76) (26–69) (17–33) (40–4)
Years since diagnosis 9 7 4 13 24 2
(range) (1–33) (1–19) (1–8) (2–27) (17–33) (1–16)
Walking:wheelchair 100:127 23:93 20:7 38:24 13:2 6:1
Normal hand function: restricted (yes:no) 176:51 86:30 26:1 45:17 14:1 5:2
Carer dependence (yes:no) 100:127 76:40 1:26 22:40 1:14 0:7
Current bladder management
Botox 71 31 9 28 1 2
Mitrofanoff 41 20 0 13 6 2
Urostomy 23 13 2 4 3 1
CIC* 86 49 15 15 5 2
None 6 3 1 2 0 0
*CIC: Clean Intermittent Catheterization. SCI: Spinal Cord Injury. CE: Cauda Equina Syndrome. MS: Multiple Sclerosis. SB: Spina Biﬁda.
doi:10.1371/journal.pone.0159394.t002
Table 3. Health State Utility Values (HSUV).
HRQoL parameters Input value Reference
TAI HSUV 0.565 IPD set*
Failed SBC HSUV 0.548 IPD set*
Surgical interventions HSUV 0.548 Assumption: same as failed SBC
Stoma HSUV 0.505 Furlan 2007 [27]
UTI decrement -0.060 NICE 2012 [28]
Hospitalisation decrement -0.100 Watt 2012 [29]
*Individual Patient Data (IPD) set. HSUV: Health State Utility Values. NICE: National Institute for health and
Care Excellence.
doi:10.1371/journal.pone.0159394.t003
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Unit costs
Drug and product costs were obtained from the NHS Electronic Drug Tariff [19] and the most
recent version of the British National Formulary [20]. Staff and stoma costs were obtained
from the most recent Unit Costs of Health and Social Care report [21] and NHS reference
costs 2013–14 [22]. All other costs were sourced from the literature on NBD management and
are presented in Table 4.
Model outputs
The deterministic Markov model predicts the number of FI and UTI episodes, Quality
Adjusted Life Years (QALYs) and stoma surgeries, when initiating TAI versus continuing SBC
in patients with NBD. Incremental cost effectiveness ratios (ICERs) are presented by compar-
ing the cost and consequences of the two treatment options. A cost-effectiveness plane was
applied to illustrate the relation between incremental cost and QALYs gained. Results are con-
sidered cost-effective within a £20,000 to £30,000 per QALY gained range as recommended by
the UK National Institute for Health and Care Excellence (NICE) [23].
Sensitivity analysis
One-way deterministic sensitivity analyses were conducted by varying HSUVs by ±0.02 and all
other input values by ±25%. A probabilistic sensitivity analysis (PSA) was conducted to capture
the effect of overall parameter uncertainty on the results. In the absence of information on the
dispersion of parameters, standard errors were set equal to 10% of the mean parameter esti-
mate. A value was drawn from an appropriate distribution for each parameter (with the excep-
tion of list prices) for 1,000 simulations and the impact on the costs and QALYs was plotted on
a cost-effectiveness plane. A cost-effectiveness acceptability curve (CEAC) was also generated
to represent the probability of cost-effectiveness of TAI relative to failed SBC across a series of
willingness to pay (WTP) thresholds.
Results
Base case
Based on the applied data input and model assumptions the model predicts that a patient with
NBD diagnosed at age 30 using TAI will experience a 36% reduction in the number of FI epi-
sodes experienced over their lifetime (from 2,069 to 1,322 episodes). The model also predicted
a 35% reduction in the frequency of stoma surgery associated with the use of TAI. Further-
more, based upon self-reported recall data, the model estimated 4.46 fewer episodes (29%
reduction) of treated UTIs using TAI compared with continuing SBC alone.
Overall, these clinical benefits result in an improvement in QALYs for patients receiving
TAI of 0.40 compared with patients continuing SBC. The deterministic total costs and effects,
and ICERs per effect outcome, are presented in Table 5. The model estimated a lifetime total
cost-savings of £21,768 per patient using TAI compared with SBC. ICERs were all dominant
(offering increased benefits at lower cost) regardless of whether benefits are expressed as
QALYs, episodes of FI, UTIs and stoma surgery avoided.
Sensitivity analysis
The univariate sensitivity analyses showed that TAI was also the dominant treatment strategy
associated with a cost-saving and increase in benefits, when varying key input variables ±25%.
HSUV for both TAI and SBC were the most sensitive input variables. Varying the frequency
Long-Term Cost-Effectiveness of Transanal Irrigation
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Table 4. Costs and resource use.
Standard Bowel Care Costs Frequency References
Bulking agent: Fybogel sachet (pack of 30) £2.29 Daily [20]; IPD set*
Softener: docusate (pack of 100) £6.98 Daily [20]; IPD set*
Stimulant: bisacodyl (pack of 100) £3.43 Daily [20]; IPD set*
Osmotic: Movicol (pack of 50) £11.13 Daily [20]; IPD set*
Suppository glycerine (pack of 12) £1.94 Every alternate day [20]; IPD set*
Suppository bisacodyl (pack of 12) £1.57 Every alternate day [20]; IPD set*
Enema: Norgalax 10g £0.66 Every alternate day [20]; IPD set*
Anal plug (pack of 20) £44.89 Daily and per FI episode [19]
Incontinence pad (pack of 7) £5.95 Daily and per FI episode [30]
Peristeen TAI Costs Frequency References
System £74.78 Irrigation every other day; replaced
every 6 months
[19], [10]
Rectal catheters £130.33 Irrigation every other day; replaced
every month
[19], [10]
Initial consultation £142.00 One-off Consultant visit, [21]
Follow-up phone call £100.00 Three 15-minute calls Nurse, day ward, [21]
Surgical interventions Costs Frequency References
SNS Procedure £9,368.00 One-off [23], inﬂated
SNS Follow-up £6,286.00 Every 7 years [23], inﬂated
SARS Procedure £7,770.00 One-off [31] (10,500 EUR converted to GBP
at 1 EUR = 0.74 GBP and inﬂated)
SARS Follow-up £118.92 2-monthly consultation Colorectal surgery outpatient
attendance, [22]
ACE Procedure (weighted average of non-elective inpatient stay
of major procedures for 19 years and over, all CC scores)
£3,870.33 One-off Major large intestine procedure, [22]
ACE Follow-up £118.92 2-monthly consultation Colorectal surgery outpatient
attendance, [22]
Stoma surgery Costs Frequency References
Surgery (weighted average of non-elective inpatient stay of very
complex, complex and major procedures for 19 years and over, all
CC scores)
£7,459.76 One-off Major large intestine procedure, [22]
Colostomy bag (pack of 30) £87.00 2 times daily [19]
Belt (pack of 1) £6.78 Monthly [19]
Skin barrier (pack of 30) £22.24 2 times daily [19]
Adhesive remover (pack of 30) £14.96 2 times daily [19]
HCP visits and caregiver Costs Frequency References
Consultant £142.00 Annually (0.88, TAI; 1.04, SBC) [21]; IPD set*
Dietician £37.00 Annually (0.19, TAI; 0.57, SBC) [21]; IPD set*
General Practitioner £234.00 Annually (2.89, TAI; 3.75, SBC) [21]; IPD set*
Caregiver salary (time spent on NBDmanagement) £24.00 Daily (19 minutes for 25% of TAI
patients; 26 minutes for 45% of
SBC patients)
[21]; [12]; IPD set*
Adverse events Costs Frequency References
Hospitalizations Annually (0.28, TAI; 1.37 SBC) IPD set*
Gastrointestinal infection (weighted average of non-elective
inpatient stay with multiple interventions, with single intervention
and without intervention, all CC scores)
£1,998.84 Gastrointestinal infection, [22]
Pressure ulcer management £24,214.00 [32], inﬂated
Falls or other trauma (weighted average of non-elective inpatient
stay, all CC scores)
£2,326.32 Falls without speciﬁc cause, [22]
(Continued)
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with which TAI is administered per week had the third greatest impact on the results. A Tor-
nado diagram with the most important input variables is shown in Fig 2.
The incremental results of the probabilistic sensitivity analysis are presented in Fig 3. The
mean incremental cost and QALYs lie in the dominant, lower right quadrant of the CE plane,
indicating a positive effect on health-related quality of life (HRQOL) and that TAI is a cost sav-
ing technology. However, the dispersion of the simulations also demonstrates some uncertainty
in the incremental costs and outcomes results with simulations in all four quadrants. A cost-
saving is demonstrated in 96% of simulations, suggesting that while there is uncertainty about
the magnitude of the cost-saving associated with TAI, it is a very robust finding that TAI is a
cost-saving treatment strategy over the life expectancy of an SCI patient. The dispersion in
incremental QALYs suggests that, as seen with the one-way sensitivity analysis, the model is
most sensitive to HSUV inputs.
Discussion
When new interventions and technologies are introduced to the market, they are often more
effective than existing treatment strategies, but also more costly to society. To ensure optimal
use of NHS resources, a cost-effectiveness threshold of £20,000-£30.000 per QALY gained has
been recommended by NICE to establish which interventions represent good value for money
and should be implemented (NICE 2013). In the present study, a deterministic Markov model
was used to investigate the long-term cost-effectiveness of initiating TAI in patients with NBD
who have failed SBC for more than six months. A unique real-life data set of NBD patients was
applied in the model. The results revealed a lifetime cost saving of £21,768 and a QALY
improvement of 0.40 when using TAI compared with SBC. A reduction in FI episodes, number
of treatment-required UTIs, and stoma surgery were also shown. This indicates that TAI is
Table 4. (Continued)
Abdominal pain (weighted average of non-elective inpatient stay
with and without intervention)
£1,432.09 Abdominal pain with and without
interventions, [22]
UTI (weighted average non-elective of inpatient stay with and
without interventions, all CC scores)
UTI treatment requiring antibiotics £167.77 Annually (0.67, TAI; 1.37 SBC) [33]; IPD set*
Peristomal skin complications £34.89 61% annually [34]
Hernia complication £3,355.69 18% every 4 months Hernia procedure, [22]
Episodes of fecal incontinence Monthly (1.5. TAI; 3.5 SBC) IPD set*
*Individual Patient Data (IPD) set. SNS: Sacral Nerve Stimulation. SARS: Sacral Anterior Root Stimulation. ACE: Antegrade Continence Enema.
doi:10.1371/journal.pone.0159394.t004
Table 5. Cost-effectiveness results summary.
Comparator Total costs QALYs FI episodes UTI Stoma
Peristeen TAI £148,951 11.60 1322* 11.06* 0.46*
Failed SBC £170,719 11.20 2069* 15.52* 0.71*
Incremental -£21,768 0.40 -746.49 -4.46 -0.25
% change -13% 4% -36%† -29%† -35%†
ICER — Dominant Dominant Dominant Dominant
*Predicted absolute average event counts experienced over a patient lifetime.
†Relative reduction over a lifetime for treatment with Peristeen TAI compared with failed SBC.
doi:10.1371/journal.pone.0159394.t005
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both clinically superior for the patients and cost saving for society compared with continuing
SBC alone. The practical implication is therefore that TAI should be implemented as standard
treatment for patients failing SBC.
The findings confirm the results from a previously published cost-effectiveness analysis of
TAI [12] showing a lower total cost to society using TAI compared with conservative bowel
management. However, the 2009 study by Christensen et al [12] was based on efficacy data
retrieved from a 10-week RCT where the effect of TAI was investigated in a homogeneous
group of SCI patients with NBD [11]. RCTs are considered the gold standard to evaluate effi-
cacy and safety under carefully controlled settings. This, however, can also be a drawback, as it
will only reveal the efficacy in a limited study population and with a short-term time horizon.
The previous cost-effectiveness evaluation of Peristeen based on the RCT study by Christensen
et al [12] and the present study increases the generalizability of the findings by covering both
the short-term controlled environment and the long-term real-life setting with a more hetero-
geneous mixed NBD study population.
In the present study, EQ-5D was used to evaluate the impact on HRQoL. The EQ-5D is a
generic HRQoL-instrument used and recognized by NICE and other international HTA agen-
cies as the preferred measure of health outcomes in health economic evaluations. The esti-
mated QALY gain of 0.40 is modest given the increased patient benefits retrieved using TAI,
e.g. reduction in episodes of FI, indicating that EQ-5D may be too generic to measure improved
quality of life related to bowel management for the NBD population. In the study by Christen-
sen et al [11], three validated bowel function-scoring systems and a symptom-related quality
of-life questionnaire were used to evaluate severity of symptoms and all four showed significant
improvement after 10 weeks usage of TAI. NBD bowel scores were also collected for the real-
life data set used in the present study, although not included in the model. At baseline 71% of
patients had an NBD score above 14, indicating a severe level of bowel dysfunction [24,25]. At
the one-year follow-up after initiating TAI 32% of the patients had an NBD score above 14,
representing a 55% reduction. One explanation to the small observed QALY-improvement
could therefore be that EQ-5D, because of its generic form, does not capture the full HRQoL
effects of TAI in the NBD population. In contrast, Liu et al [26] found a significant correlation
Fig 2. Tornado diagram.
doi:10.1371/journal.pone.0159394.g002
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between the severity of NBD and HRQL using the generic, but more detailed SF-36 outcome
measure, which supports the argument that EQ-5D might be insensitive in this population.
This discrepancy indicates that important health benefits risk being overlooked and the topic
warrants further research, for example by also analyzing the EQ-5D VAS scores or by including
different outcome measures.
Transition states and the majority of effect input in the present model were based on pro-
spective real-life data collected in the UK. Transferability of the model to a setting outside of
the UK would require that the analysis consider clinical practice variations, e.g. that some clin-
ics may favor stoma surgery, whereas others will continue insufficient bowel management solu-
tions to avoid surgery.
The estimated reduced numbers of UTIs seems low compared with results from Christensen
et al [11]. However, in the present study, the frequency of UTI was based on self-reported num-
ber of treatment required UTIs, which introduces a risk of recall bias. Also, this cohort included
Fig 3. Cost-effectiveness plane.WTP:Willingness to pay: linear threshold corresponds to theWTP value used by NICE in making reimbursement
decisions (£30.000 per QALY gained). Each quadrant corresponds to one incremental cost option (cost saving, not cost saving) and one incremental
benefit option (more/less benefit than comparator therapy).
doi:10.1371/journal.pone.0159394.g003
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a significant proportion with advanced bladder management strategies and less than 40% used
intermittent self-catheterization, which could also influence the number of reported UTIs.
Living with a chronic condition such as NBD and the associated risks of bowel leakage or
constipation have a large impact on the quality of life [5]. Finding the right bowel management
solution is important both for the individual and for society. In the treatment of chronic dis-
eases, it is important to assess the long-term effects and costs. Using costs and real-life data
from a single country, this cost-effectiveness analysis has demonstrated that it is possible to
model a chronic disease course along with lifetime costs when adopting a limited set of conser-
vative assumptions.
Conclusion
This study demonstrates that TAI is a cost saving treatment strategy for patients with NBD
who have failed SBC for more than six months. In addition, TAI improves QALYs and reduces
episodes of FI, UTIs and the risk of stoma surgery. The time horizon of the study was based on
a lifetime perspective and a healthcare provider perspective. The sensitivity analysis showed
that the results were robust to changes in key variables. TAI improves health and health related
quality of life for people suffering from NBD while also saving costs to society and should
therefore be implemented as a standard treatment for this patient group, when treatment with
SBC is insufficient.
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